1217809-88-5

Usage

Uses

Used in Pharmaceutical Industry:
(S)-Cinacalcet hydrochloride is used as a therapeutic agent for managing conditions such as chronic kidney disease and hyperparathyroidism. It is employed to regulate the body's production of parathyroid hormone, thereby controlling calcium levels in the blood and bones, which is crucial for the health of patients with these conditions.
Used in Chronic Kidney Disease Treatment:
(S)-Cinacalcet hydrochloride is used as a medication to treat secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis. Its calcimimetic action helps to maintain calcium and phosphorus levels within the desired range, reducing the risk of complications associated with abnormal calcium metabolism.
Used in Hyperparathyroidism Management:
(S)-Cinacalcet hydrochloride is used as a treatment for primary hyperparathyroidism, a condition characterized by the overproduction of parathyroid hormone. By increasing the sensitivity of the calcium-sensing receptor to extracellular calcium, it helps to normalize parathyroid hormone levels and associated calcium imbalances.

Upstream product

• 15297-33-3 (S)-N-methyl-N-1-(1-naphthyl)ethyl amine 
• 349-76-8 3'-(trifluoromethyl)acetophenone 
• 3886-70-2 (R)-1-(1-Naphthyl)ethylamine 

Downstream Products

• 1301700-82-2 1-chloroethyl carbamate cinacalcet 

Relevant academic research and scientific papers

Hydroxoiridium-Catalyzed Hydroalkylation of Terminal Alkenes with Ureas by C(sp3)?H Bond Activation

Direct alkylation of a methyl group, on di- and trisubstituted ureas, with terminal alkenes by C(sp3)?H bond activation proceeded in the presence of a hydroxoiridium/bisphosphine catalyst to give high yields of the corresponding addition products. The hydroxoiridium/bisphosphine complex generates an amidoiridium intermediate by reaction with ureas having an N?H bond.

Hydrochloric cinacalcet preparation method

The invention discloses a hydrochloric cinacalcet preparation method. Commercial m-(trifluoromethyl) acetophenone, formaldehyde, (R)-1-(1-naphthyl) ethylamine and the like serve as raw materials, an intermediate (R)-3-(1-(naphthalene-1-base) ethyl amino)-1-(3-(trifluoromethyl) phenyl) propane-1-ketone is prepared by multi-component Mannich reaction and subjected to reduction reaction to prepare cinacalcet, and the cinacalcet reacts with hydrochloric acid, so that hydrochloric cinacalcet can be prepared. The preparation method is short in synthetic route, low in raw material cost, low in price, safe in normal pressure reaction operation and suitable for large-scale production and has good social and economic benefits, and metal zinc amalgam reducing agents are used. Experiments prove that the recrystallization yield of the cinacalcet can reach 93.4% or more, the purity of the cinacalcet can reach 99.6% or more, the yield of the hydrochloric cinacalcet can reach 94.2% or more, and the purity of the hydrochloric cinacalcet can reach 99.7% or more.